Abstract
The consumption of N-ethyl-3,4-methylenedioxyamphetamine (MDE, 1), an analogue of ecstasy, can be detected by direct in situ HPTLC-FTIR measurement of the main metabolite N-ethyl-4-hydroxy-3-methoxyamphetamine (HME, 2). HME (2) can, like the other important metabolite 3,4-methylenedioxyamphetamine (MDA, 3) and unchanged MDE (1), be determined quantitatively in urine by HPTLC-UV after two-step automatic development. The results have been compared with those obtained using an HPLC method. The differences were not generally significant. Small deviations were attributable to the different sample preparation methods necessary. The working range for the HPTLC method was between 0.1 and 8.2 μg/ml and for the HPLC method between 0.2 and 60.0 μg/ml. The method standard deviations were 2.66–4.91% (HPTLC) and 0.48–3.67% (HPLC).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Chromatography B: Biomedical Sciences and Applications
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
